Active Stock’s News Update: Juno Therapeutics Inc (NASDAQ:JUNO), Corcept Therapeutics Incorporated (NASDAQ:CORT)

On Tuesday, Shares of Juno Therapeutics Inc (NASDAQ:JUNO), subtract -1.88% and closed at $32.35 in the last trading session. The last trading range of the stock ranges between $30.73 and $33.00. The company’s Market capitalization is $3.56 Billion with the total Outstanding Shares of 105.87 million. During the 52-week trading session the minimum price at which share price traded, registered at $22.37 and reached to max level of $57.82. The EPS of company is strolling at -2.80. Juno Therapeutics, Inc. (JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, recently stated financial results and business highlights for the third quarter 2016.

“JCAR017, a key product candidate of our CD19 platform, has shown encouraging preliminary efficacy and safety results in NHL and pediatric ALL. At the forthcoming American Society of Hematology meeting, additional data from our Phase I trial for JCAR017 in NHL patients will be presented,” said Hans Bishop, Juno’s President and Chief Executive Officer. “Progress with CAR T therapy continues as we strive to bring these innovative product candidates to patients battling cancer. We look forward to the forthcoming presentations at ASH, counting 11 total presentations from a number of ongoing and accomplished studies.”

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT), dropped -2.36% and closed at $9.51 in the last trading session. The last trading range of the stock ranges between $8.96 and $10.00. The company’s Market capitalization is $1.06 Billion with the total Outstanding Shares of 111.03 million. During the 52-week trading session the minimum price at which share price traded, registered at $3.22 and reached to max level of $10.00. The EPS of company is strolling at 0.04. Financial Highlights

Third quarter revenue of $21.7 million, a 64 percent increase from the third quarter of 2015

Third quarter GAAP net income of $0.02 per share, contrast to a GAAP net loss of $0.01 per share in the third quarter of 2015

Apart From non-cash expenses, third quarter non-GAAP net income of $0.04 per share, contrast to non-GAAP net income of $0.02 per share in the third quarter of 2015

Company increases 2016 revenue guidance to $79-82 million

Cash balance at September 30, 2016 increases to $47.9 million

Clinical Highlights

Final results of Phase 1/2 trial of mifepristone combined with eribulin (Halaven®) to treat triple-negative breast cancer to be presented at San Antonio Breast Cancer Symposium, December 2016

Phase 2 trial of selective cortisol modulator CORT125134 to treat patients with Cushing’s syndrome and Phase 1/2 trial to treat solid-tumor cancers enrolling patients

Next-generation selective cortisol modulators CORT122928, CORT125281 and CORT118335 on track to enter clinic in 2017

Leave a Reply

Your email address will not be published. Required fields are marked *